Join

Compare · ARGX vs OKYO

ARGX vs OKYO

Side-by-side comparison of argenx SE (ARGX) and OKYO Pharma Limited (OKYO): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ARGX and OKYO operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
  • ARGX is the larger of the two at $52.96B, about 990.6x OKYO ($53.5M).
  • Over the past year, ARGX is up 50.5% and OKYO is down 29.1% - ARGX leads by 79.6 points.
  • OKYO has been more active in the news (9 items in the past 4 weeks vs 4 for ARGX).
  • ARGX has more recent analyst coverage (25 ratings vs 2 for OKYO).
PerformanceARGX+50.48%OKYO-29.07%
2025-06-24+0.00%2026-06-23
MetricARGXOKYO
Company
argenx SE
OKYO Pharma Limited
Price
$853.73-5.62%
$1.61+1.90%
Market cap
$52.96B
$53.5M
1M return
+4.55%
-3.01%
1Y return
+50.48%
-29.07%
Sector
Health Care
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ
NASDAQ
IPO
2017
2022
News (4w)
4
9
Recent ratings
25
2
ARGX

argenx SE

argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.À.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

OKYO

OKYO Pharma Limited

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. It is developing OK-101 for the treatment of dry eye disease; and OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. The company is also developing chemerin and chemerin analogues to treat the cytokine release syndrome associated with COVID-19 infections and other conditions, such as acute respiratory distress syndrome. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

Latest ARGX

Latest OKYO